The transaction provides Edgewise with the capital necessary to accelerate development of its core cardiovascular assets, specifically EDG-7500 and EDG-15400. Company leadership indicated that the proceeds are expected to fully fund the clinical progression of EDG-7500 through potential regulatory approval. To maintain continuity for the muscular dystrophy program, a core group of Edgewise employees supporting sevasemten will transition to the French-based Servier.
In section Releases
Edgewise Therapeutics Sells Muscular Dystrophy Portfolio to Servier
Edgewise Therapeutics has finalized the sale of its sevasemten program and muscular dystrophy business to the international pharmaceutical group Servier for $1.55 billion in upfront cash. The deal, which includes potential milestone payments totaling $1.1 billion, marks a definitive pivot for the company toward its cardiovascular drug pipeline.
Following the divestiture, Edgewise is focusing its resources on its remaining pipeline. The company plans to initiate a Phase 3 trial for EDG-7500 in the fourth quarter of 2026, building on positive data from recent Phase 2 studies in hypertrophic cardiomyopathy. Meanwhile, Servier gains ownership of a late-stage therapy for Becker and Duchenne muscular dystrophy, a portfolio that has already secured Orphan Drug and Fast Track designations from the FDA. The acquisition aligns with Servier’s long-term expansion into rare neurological diseases.
Comments (0)
No comments yet. Be the first!